Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 116
Selected: 0
NCT IDTitle
NCT00058786Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells
NCT01945619Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)
NCT00586274Use of Rft5-Dga to Deplete Alloreactive Cells for Pts With Fanconi Anemia After Haploidentical SCT
NCT01070797Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
NCT00578903Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia
NCT00902044Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
NCT01555892Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
NCT02932956Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
NCT00539695Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD
NCT01713439Allogeneic Neuroblastoma Cells for Relapsed/ Refractory Neuroblastoma, CYCHEALL
NCT024397883RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
NCT00040469Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies
NCT00368082Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)
NCT01953900iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma
NCT05103631Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
NCT00590083Administration of Virus-Specific Cytotoxic T-Lymphocytes
NCT01192464EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma
NCT04401410Anti-SARS Cov-2 T Cell Infusions for COVID 19
NCT00048412Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
NCT07297160CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors
NCT00840853Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
NCT03774654CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
NCT00880789Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
NCT01316146Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30)
NCT06815432GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma
NCT03635632C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
NCT02287311Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
NCT00953420Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes
NCT02276820Most Closely Human Leukocyte Antigen (HLA)-Matched Adenovirus-specific T Lymphocytes (Viralym-A)
NCT00056966Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
NCT03690011Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
NCT04219163Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
NCT02050347Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)
NCT03192462TAA Specific Cytotoxic T Lymphocytes in Patients With Pancreatic Cancer
NCT00586391CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL
NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas
NCT01702961Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease
NCT03081910Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
NCT02442297T Cells Expressing HER2-specific Chimeric Antigen Receptors(CAR) for Patients With HER2-Positive CNS Tumors
NCT00590460Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia
NCT00516087LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)
NCT00515957Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL)
NCT02475707Administration of Donor MultiTAA-Specific T Cells for ALL
NCT00368355T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
NCT00062868LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
NCT05134740(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL).
NCT02291848Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
NCT00058604Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
NCT00889954Her2 and TGFBeta Cytotoxic T Cells in Treatment of Her2 Positive Malignancy
NCT01447056Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases